We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

230 hedge funds and large institutions have $3.57B invested in Amicus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 91 increasing their positions, 64 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 64

27% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 33

22% more call options, than puts

Call options by funds: $8.86M | Put options by funds: $7.25M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

11% more capital invested

Capital invested by funds: $3.2B → $3.57B (+$367M)

4% more funds holding

Funds holding: 222230 (+8)

5.45% less ownership

Funds ownership: 109.55%104.1% (-5.5%)

Holders
230
Holders Change
+8
Holders Change %
+3.6%
% of All Funds
3.7%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
42
Increased
91
Reduced
64
Closed
33
Calls
$8.86M
Puts
$7.25M
Net Calls
+$1.61M
Net Calls Change
-$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$338M +$3.04M +270,000 +1%
ACA
2
Avoro Capital Advisors
New York
$327M
Vanguard Group
3
Vanguard Group
Pennsylvania
$324M +$7.51M +667,309 +3%
RG
4
Redmile Group
California
$247M -$16.5M -1,469,402 -7%
BlackRock
5
BlackRock
New York
$246M +$2.7M +239,526 +1%
Morgan Stanley
6
Morgan Stanley
New York
$218M +$7.38M +655,841 +4%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$167M -$179M -15,857,681 -54%
JP Morgan Chase
8
JP Morgan Chase
New York
$165M -$8.9M -790,337 -6%
State Street
9
State Street
Massachusetts
$148M +$716K +63,627 +0.5%
PAI
10
Palo Alto Investors
California
$128M +$7.27M +645,948 +7%
PAMS
11
Pictet Asset Management (Switzerland)
Switzerland
$103M +$55.7M +4,945,650 +142%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$99M +$574K +50,972 +0.6%
Macquarie Group
13
Macquarie Group
Australia
$85M +$904K +80,286 +1%
Norges Bank
14
Norges Bank
Norway
$65.9M +$11.7M +1,043,346 +24%
Fiera Capital (Canada)
15
Fiera Capital (Canada)
Quebec, Canada
$63.4M +$13.2M +1,172,602 +29%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$59.7M +$1.89M +167,542 +4%
AG
17
Artal Group
Luxembourg
$48.8M
Northern Trust
18
Northern Trust
Illinois
$32.9M +$381K +33,885 +1%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$30.4M -$3.4M -302,420 -11%
Bank of America
20
Bank of America
North Carolina
$28.7M +$3.24M +287,852 +14%
BC
21
Boxer Capital
California
$28.4M
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$27.3M -$7.54M -670,171 -23%
William Blair Investment Management
23
William Blair Investment Management
Illinois
$25.7M +$178K +15,822 +0.8%
NHAS
24
Novo Holdings A/S
Denmark
$25.6M -$46.2K -4,100 -0.2%
Charles Schwab
25
Charles Schwab
California
$25.2M +$501K +44,518 +2%

FOLD Hedge Fund Activity: Q4 2022 in Review

230 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2022, worth a combined $3.57B — up 11% from $3.2B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new FOLD positions and 33 closed out — a net gain of 9 holders — while 91 added to existing stakes and 64 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $55.7M. The largest seller was Janus Henderson Group, cutting an estimated $179M.

  • 230 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2022, up from 222 in Q3 2022.
  • Funds reported $3.57B of Amicus Therapeutics stock for Q4 2022, up 11% quarter-over-quarter.
  • 42 funds opened new Amicus Therapeutics positions in Q4 2022 and 33 closed out, a net change of +9 holders.
  • The largest Amicus Therapeutics buyer in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $55.7M added.
  • The largest Amicus Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $179M sold.

Based on aggregated 13F filings for Q4 2022.